Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;39(7):2301-2306.
doi: 10.1007/s00345-021-03601-z. Epub 2021 Feb 10.

Reasons to consider prostatic artery embolization

Dominik Abt  1 , Hans-Peter Schmid  2 , Mark J Speakman  3
Affiliations
Review

Reasons to consider prostatic artery embolization

Dominik Abt et al. World J Urol. 2021 Jul.

Abstract

Purpose: Prostatic artery embolization (PAE) has emerged as a truly minimally invasive treatment option for patients with lower urinary tract symptoms presumed secondary to benign prostatic obstruction (LUTS/BPO) over the last few years and is now supported by evidence-based international guidelines. Here, we provide an overview on the profile of PAE based on the most relevant and recent literature.

Methods: A comprehensive review of literature on PAE was conducted on PubMed-Medline. The most relevant literature was summarized narratively.

Results: While there is still a lack of long-term data, efficacy and safety data have been published for the short to mid-term. As with any minimally invasive technique, relief of bladder outlet obstruction is less pronounced after PAE compared to more invasive resective techniques. This is likely to be associated with higher re-intervention rates during the longer term. However, due to its beneficial safety profile, PAE represents an interesting option for many patients and could fill a niche between pharmacotherapy and formal surgical intervention. Given its unique treatment approach, i.e. endovascular instead of transurethral, PAE has a clearly different profile compared to other minimally invasive treatments. Performance with local anesthesia with possible continuation of anticoagulant drugs and no upper prostate size limit are the most important advantages of PAE.

Conclusion: PAE represents a valuable supplement in the treatment armamentarium of LUTS/BPH if patients are selected appropriately.

Keywords: Benign prostatic hyperplasia; Lower urinary tract symptoms; Minimally-invasive treatment; Prostate embolization; Prostatic artery embolization.

PubMed Disclaimer

References

    1. Speakman MJ, Cornu JN, Gacci M et al (2019) What is the required certainty of evidence for the implementation of novel techniques for the treatment of benign prostatic obstruction? Eur Urol Focus 5(3):351–356. https://doi.org/10.1016/j.euf.2019.05.014 - DOI - PubMed
    1. Emberton M, Marberger M, de la Rosette J (2008) Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the prostate research on behaviour and education (PROBE) survey. Int J Clin Pract 62(1):18–26. https://doi.org/10.1111/j.1742-1241.2007.01635.x - DOI - PubMed - PMC
    1. Gravas S, Cornu JN, Gacci M, et al. (2020) EAU Guidelines on Management on Non-neurogenic Male LUTS. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ .
    1. McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association Guideline: management of benign prostatic hyperplasia (BPH). Revised, 2010. https://www.auanet.org benign-prostatichyperplasia-(2010-reviewed-and-validity-confirmed-2014).
    1. Thomas AW, Cannon A, Bartlett E et al (2005) The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int 96(9):1301–1306. https://doi.org/10.1111/j.1464-410X.2005.05815.x - DOI - PubMed

LinkOut - more resources